芪苓益气片治疗HIV感染者及AIDS患者110例自身对照研究
|
摘要
目的：通过自身对照观察芪苓益气片治疗HIV感染者及AIDS患者的临床疗效及对CD4和病毒载量的影响。
方法：在西昌、乐山、攀枝花、成都选取符合条件的HIV感染者及AIDS患者110例,采用自身对照方法,给予芪苓益气片每日3次每次6片口服12月治疗,每月随访一次并记录用药后患者临床症状、体征积分、卡洛夫斯基积分、体重、感冒次数的情况及每三月检查并记录一次血CD4值及病毒载量的情况,分别比较用药前与用药后3月、6月、9月、12月患者临床症状、体征积分、卡洛夫斯基积分、体重、感冒次数、血CD4值及病毒载量的变化情况以对临床疗效进行综合分析。
结果：在总积分、大部分症状体征积分、卡洛夫斯基积分、体重、感冒次数改善方面,自身治疗前后比较,差异有意义。CD4值变化方面治疗前后分别比较差异均有统计学意义。而且CD4不同的患者对本药的效用有区别,表现为350／ul及以上有效、稳定的患者较其它水平患者高。病毒载量的改善方面在治疗前与治疗3、12月末比较差异有意义,但在治疗6月、9月末差异无意义。病毒载量在100000copies/ml以上的患者疗效不明显。通过研究表明疗后CD4值与感冒次数及总积分相关性不明显。患者性别、年龄、病程与疗效无明显相关性。
结论：芪苓益气片是在中医辨证论治的基本理论指导下,欲通过调节机体抗病防卫机制,增强机体本身对外界致病因素的抵抗力,以达到抗HIV感染和改善症状体征的目的。从结果来看,芪苓益气片可能对HIV感染者及AIDS患者显示出疗效,值得进一步研究。
Objective:Through clinical observation of Qi Ling Yi Qi tablets to sdudy the therapy of HIV-infected persons and AIDS patients and to provide the impact of experimental indicators.
Methods:110 cases with HIV-infected persons and AIDS patients were chosen by certain standards and given Qi Ling Yi Qi tablets oral treatment for 3 times a day and each six tablets about 12 months,Who came from Xi Chang、Le Shan、Pan Zhi Hua and Cheng Du.Use the designs of self-contrast before and after treatment. Once a month record the patient's condition after treatment with clinical symptoms and signs score karnovsky score, weight, number of influenza.Once three months check and record the value of blood CD4 and viral load. We compared the patient's condition with clinical symptoms and signs score, karnovsky score, weight, number of influenza,the value of blood CD4 and viral load respectively before and after treatment of 3 months,6 months,9 months and 12 months to carry out a comprehensive analysis of clinical efficacy.
Results:In the total score, the majority of clinical symptoms and signs score, karnovsky score, weight, number of influenza, the value of blood CD4,self-contrast before and after treatment, there was a significant difference.The patients with different value of CD4 had different effectiveness after using the medicine, The patients of 350/ul and above in effective and stable is more than other patients. In viral load, after treatment of 3,12 months, there was a difference. About viral load above 100000copies/ml, the effects were not obvious.The study shows that after treatment the correlation of the value of blood CD4 with number of influenza and signs score, the total score and Patient's gender, age, course of disease with effects were not obvious.
Conclusion:In the basic theory of TCM syndrome differentiation Qi Ling Yi Qi tablets can regulate body's resistance and enhance the body's own resistance to external pathogenic factors in order to achieve anti-HIV infection and improve the symptoms and signs. From the results, Qi Ling Yi Qi tablets may show efficacy to HIV-infected persons and AIDS patients.It is worth further study.
方法：在西昌、乐山、攀枝花、成都选取符合条件的HIV感染者及AIDS患者110例,采用自身对照方法,给予芪苓益气片每日3次每次6片口服12月治疗,每月随访一次并记录用药后患者临床症状、体征积分、卡洛夫斯基积分、体重、感冒次数的情况及每三月检查并记录一次血CD4值及病毒载量的情况,分别比较用药前与用药后3月、6月、9月、12月患者临床症状、体征积分、卡洛夫斯基积分、体重、感冒次数、血CD4值及病毒载量的变化情况以对临床疗效进行综合分析。
结果：在总积分、大部分症状体征积分、卡洛夫斯基积分、体重、感冒次数改善方面,自身治疗前后比较,差异有意义。CD4值变化方面治疗前后分别比较差异均有统计学意义。而且CD4不同的患者对本药的效用有区别,表现为350／ul及以上有效、稳定的患者较其它水平患者高。病毒载量的改善方面在治疗前与治疗3、12月末比较差异有意义,但在治疗6月、9月末差异无意义。病毒载量在100000copies/ml以上的患者疗效不明显。通过研究表明疗后CD4值与感冒次数及总积分相关性不明显。患者性别、年龄、病程与疗效无明显相关性。
结论：芪苓益气片是在中医辨证论治的基本理论指导下,欲通过调节机体抗病防卫机制,增强机体本身对外界致病因素的抵抗力,以达到抗HIV感染和改善症状体征的目的。从结果来看,芪苓益气片可能对HIV感染者及AIDS患者显示出疗效,值得进一步研究。
Objective:Through clinical observation of Qi Ling Yi Qi tablets to sdudy the therapy of HIV-infected persons and AIDS patients and to provide the impact of experimental indicators.
Methods:110 cases with HIV-infected persons and AIDS patients were chosen by certain standards and given Qi Ling Yi Qi tablets oral treatment for 3 times a day and each six tablets about 12 months,Who came from Xi Chang、Le Shan、Pan Zhi Hua and Cheng Du.Use the designs of self-contrast before and after treatment. Once a month record the patient's condition after treatment with clinical symptoms and signs score karnovsky score, weight, number of influenza.Once three months check and record the value of blood CD4 and viral load. We compared the patient's condition with clinical symptoms and signs score, karnovsky score, weight, number of influenza,the value of blood CD4 and viral load respectively before and after treatment of 3 months,6 months,9 months and 12 months to carry out a comprehensive analysis of clinical efficacy.
Results:In the total score, the majority of clinical symptoms and signs score, karnovsky score, weight, number of influenza, the value of blood CD4,self-contrast before and after treatment, there was a significant difference.The patients with different value of CD4 had different effectiveness after using the medicine, The patients of 350/ul and above in effective and stable is more than other patients. In viral load, after treatment of 3,12 months, there was a difference. About viral load above 100000copies/ml, the effects were not obvious.The study shows that after treatment the correlation of the value of blood CD4 with number of influenza and signs score, the total score and Patient's gender, age, course of disease with effects were not obvious.
Conclusion:In the basic theory of TCM syndrome differentiation Qi Ling Yi Qi tablets can regulate body's resistance and enhance the body's own resistance to external pathogenic factors in order to achieve anti-HIV infection and improve the symptoms and signs. From the results, Qi Ling Yi Qi tablets may show efficacy to HIV-infected persons and AIDS patients.It is worth further study.
引文
[1]赵辨.临床皮肤病学[M](第三版).南京：江苏科学技术出版社,2003：546-556.
[2]危健安,陆嘉明等.11省中医药治疗爱滋病项目临床技术培训资料[M].北京：中国中医研究院爱滋病中医药防治中心,2005：1-97.
[3]张学军.皮肤性病学[M](第五版).北京：人民卫生出版社,2002：201.
[4]童迎凯.爱滋病治疗的研究进展[J].生物学通报,2004,10(3)：44.
[5]张娴,方曙.中药防治艾滋病研究进展[J].中国中医药信息杂志,2000,7(1)：20.
[6]中国疾病预防控制中心.艾滋病临床治疗与护理培训教材[M] (第一版),北京：北京大学出版社,2003：194-196.
[7]危健安,陆嘉明等.11省中医药治疗爱滋病项目临床技术培训资料[M].北京：中国中医研究院爱滋病中医药防治中心,2005：2-9.
[8]杨集群,杨成,王莉玲.“AIDS”的中医药治疗[J].吉林中医药,2006,6：5.
[9]何颖.浅析艾滋病的病因病机[J].湖北中医杂志,2002,24(6)：11.
[10]李崇忠等.中医药治疗艾滋病理论的建立和临床应用[J].实用中医内科杂志,2002,16(2)：62-63.
[11]尤松鑫.艾滋病中医证治概述[J],江苏中医,1999,3(20)：3-5.
[12]王健等,中医药治疗艾滋病的现状与思考[J].中国中医药信息杂志,2001,8(12)：8.
[13]吕维柏,“八五”攻关课题中医治疗艾滋病临床总结[A]见：艾滋病人的希望[M].北京：中国中医药出版社,2000：17-26.
[14]王树,在澳大利亚用中医药治疗艾滋病的体会与研讨[J].天津中医,2000,1(1)：45.
[15]姚乃礼,中医证候鉴别诊断学[M](再版).北京：人民卫生出版社,2002：465-462.
[16]李国勤.艾滋病中医辨治体会[J].江苏中医,1994,15(2)：5-6.
[17]黄世敬,危剑安,孙利民等.中医治疗十年以上21例艾滋病例报告[J].中 国医药学报,2004,19(12)：731-732.
[18]唐照亮.中医药、针灸防治艾滋病的研究与探讨[J].安徽中医学院学报,1992,11(1)：2-4.
[19]高学敏主编.中药学[M].北京：人民卫生出版社,2004：1.
[20]宋立人,丁绪亮等主编,现代中药学大辞典[M].北京：人民卫生出版社,2001：5.
[21]云秦川. 中药黄芪的药理研究进展[J].内蒙古中医药,2004(6)：33-34.
[22]刘克敏,刘振玉.黄芪的药理作用及其在运动医学中的应用[J].现代中西医结合杂志,2005,14(17)：2346-2349.
[23]孙延涛,孙琦.黄芪的药理作用研究[J].黑龙江医药,2007,3(20)：256-257.
[24]国家中医药管理局《中华本草》编委会.中华本草精选本[M].上海：上海科学技术出版社,1998：770-774.
[25]李伟,文红梅等.白术质量标准研究[J].药物分析杂志,2001，1(3)：170.
[26]余上才,章育正等.枸杞子和白术免疫调节作用的实验研究[J].上海免疫学杂志,1994,14(1)：12.
[27]中华人民共和国药政管理局.现代实用本草(第1版)[M].北京：人民卫生出版社,1997：248.
[28]国家中医药管理局《中华本草》编委会.中华本草精选本[M].上海：上海科学技术出版社,1998：374-377.
[29]国家中医药管理局《中华本草》编委会.中华本草精选本[M].上海：上海科学技术出版社,1998：725-729.
[30]国家中医药管理局《中华本草》编委会.中华本草精选本[M].上海：上海科学技术出版社,1998：665-667.
[31]李日庆.中医外科学[M].北京：中国中医药出版社,2002：232-233.
[1]王健,许建阳.中医药治疗艾滋病的现状和前景[J].武警医学,2003,14(10)582-584.
[2]中国疾病预防控制中心.艾滋病临床治疗与护理培训教材[M].北京：北京大学医学出版社,2003：194-196.
[3]胡超军.卫生专业技术人员艾滋病防治知识会员培训教材[M].北京：中国市场出版社,2004：114-116.
[4]危剑安.艾滋病的中医药治疗[M]／中国疾病预防控制中心.艾滋病治疗与护理培训教材.北京：北京大学医学出版社,2003：124.
[5]综淑玲,关崇芬,翁新愚等.扶正祛邪中药复方对猴艾滋病模拟实验研究[J].中国实验方剂学杂志,2003,9(1)：42-44.
[6]李志勇,郭勇,罗焕亮.香豆素类化合物——抗HIV天然药物[J].生命的化学,1999,19(4)：197-198.
[7]于志萍,王昌禄,顾晓波大.豆皂苷的研究与进展[J].粮油食品科技,2002,10(3)：1-4.
[8]中国疾病预防控制中心,艾滋病临床治疗与护理培训教材[M](第1版).北京：北京大学出版社,2003：194-196.
[9]赵辨,临床皮肤病学[M](第3版).南京：江苏科学技术出版社,2001：604-607、707-709.
[10]刘翠娥.中药煎剂外用治疗[J].HIV／AIDS疾疗效分析,2005,(10)：839.
[11]顾军,刘洪普.中医药治疗艾滋病研究进展[J].Chinese Genernl practice December2003,6(12):985-986.
[12]张弛,张文远等.针灸治疗艾滋病合并面瘫疗效观察[J].中国针灸,2000,20(8)：489-490.
[13]尹勇,段丽萍.针灸治疗艾滋病23例[J].上海中医药大学学报,2002,16(2)29-30.
[14]张萍,视希娴.甘草及制剂药理有临床应用研究新进展[J].中草药,1987,28(9)：568.
[15]Jordan WE. Three open-label studies of oral interferon alpha in the trearment of HIV disense[J]. J Natl med Assoc,1994,86:47257.
[16]杨秀芝,魏丹芳.抗艾滋病药物的治疗动态[J].天津医学,1995,7(1)：57.
[17]郭大.大蒜在艾滋病中作用(附98例治疗报告)[J].综合临床医学,1994,10(3)：163.
[1]姜日文,姜秀英.艾滋病[J].中国社区医师,2002,18(15)：14.
[2]第十七届国际艾滋病大会[J].上海预防医学杂志,2008,20(9)：455.
[3]骆成榆,黄琴等.艾滋病的病因与致病机制[J].世界感染杂志,2003,3(3)：236.
[4]王家璧.艾滋病[J].北京医学,1982,14(2)：104.
[5]赵武述,膝仁,卞志强.现代临床免疫学[M].北京：人民军医出版社,1994：363—367.
[6]骆成榆,黄琴等.艾滋病的病因与致病机制[J].世界感染杂志,2003,3(3)：234.
[7]Wyagarden JB (ed). Cecil textbook of medicine.19th ed. PhiladelOhia. W BSaurrders Co,1992:1908.
[8]Bevilaegua M, Vago T, Villa M L, et al. An immu-noendocrinological hypothes is of HIV infection. Lanset,1994,343:1552.
[9]闻玉梅.医学分子病毒学[M].北京：人民卫生出版杜,1990：202—220.
[10]王凝芳.艾滋病临床研究进展[J].人民军医,1997,40(10)：605.
[11]比岛恒和.艾滋病与恶性淋巴瘤[J].日本医学介绍,1999,20(6)：259～261.
[12]森山佐知子.艾滋病与机会性感染的病理组织学特征[J].日本医学介,1999,20(6)：265～266.
[13]孟德权,姚宏.艾滋病病理学研究新进展[J].中国药物与临床,2004,4(6)：449.
[14]李太生.艾滋病的抗病毒治疗[J].临床药物治疗杂志,2005,3(5)：13—16.
[15]张耀,熊鸿燕.艾滋病治疗研究进展[J].西南国防医药,200515(5)：557-558.
[16]Borroto-Esoda K, Waters J, et al. Characterization of baseline and treatment emergent resistance mutations following one year of therapy on an entirely once a day regimen including emtricitabine[J]. In Preedings of the Ⅻ International HIV Drug Resistant Workshop,2003 June,10-14.
[17]Margot NA, Isaacson E, et aL ScDoley and M D Nfiller. Genotypic and phenotypic analyses of HIV-1 in antimtroviral-extenced patients tmted with tenofavir[J]. AⅡ,2002,16:1227-1235.
[18]Abdellah Benjahad, J6r6me Guillemont, et al.3-iodo-4-phen oxypyridinones(IOPY S), a new family of highly potent non-nucleoside inhibitors of HIV-1 reverse transcriptase[J]. Bioorganic & Medicinal Chemistry Letters,2003 Dec,13(24):4309-4312.
[19]Haas DW, Zala C, et al. Therapy with atazanavir plus saquinavir in patients failing highly active antiretroviral therapy:a randomized comparative pilot trial [J]. AIIXS,2003 Jun,17(9):1339-1349.
[20]Donnerer J, Kronawetter M, Kapper A, et al. Therapeutic Drug Moni-toting of the Hlv/AIDS Drugs Abacavir。 Zidovudine。 Efavirenz, Nevi-rapine, Indinavir, Lopinavir, and Nelfinavir. Pharmacology,2003, 69(4):197-204.
[21]Kazmierski WM. Bone L, Lawrence W. et al. CCR5 chemokine receptors: gatekeepers of HIV-1 infection. Curr Drug Targets Infect Disord,2002, 2(3):265-278.
[22]Fischl MA. Antiretroviral therapy in 1999 for antiretroviral-naive individualswith HIV infection[J]. AIDS,1999,13(suppl 1):S49-S59.
[23]Hirschel B. Opravil M. The year in review:antiretroviral treatment, [J]. AIDS,1999,13(suppl A):S177-S187.
[24]Chun TW, Davey RT Jr, Eng el D, et al. Re-emergence of HIV after stopping therapy [J]. Nature,1999,401(6756):874-875.
[25]Saag MS, Kilby JM. HIV-1 andHAART:A timeto cure. Atime to kill [J]. Nat Med,1999,5(6):609-611.
[26]Ohtaka H, Schon A, Freire E. Multidmg Resistance to HIV-1 Protease Inhibition Requires Cooperative Coupling between Distal Mutations. Biochemistry,2o03,25.42(46):13659-13666.
[27]艾滋病诊疗指南.中华医学会感染病学分会艾滋病学组制订[J].中华传染病杂志,2006,24(2)：133-144.
[28]Baltimore D. Gene therapy. IntraceUular immunization [J]. Nature.1988.335(6189):395-396.
[29]BleulCC. WuL, Hoxie JA, et al. TheHIV coreceptorscXCR4 and CCR5 are differentially expressed an d regulated on human T lymphocytes [J]. Proc Natl Acad Sci usA,1997,94(5):1925-1930.
[30]0'Brien sJ, DeanM. In search ofAIDS-resistance genes[1]. Sci Am,1997,277(3):44-51.
[31]Heilman cA, timore D. HIV vaccines-where are we going [J]? Nat Med.1998,4(5 Suppl):532-534.
[32]Hilleman MR. A sim plified vaccinologist's vaccinology and the pur-suit of avaccine against AIDS [J]. Vaccine,1998,16(8):778-793.
[33]Dickson D. (1 for governments to back development of AIDS vac-cine[J]. Nature,1999,401(6748):4.
[34]CafaroA. Caputo A. FracassoC, et al. Control of SHIV-89.6P-infection of cynomolgus Fllonkeys by HIV.1 Tat protein vaccine[J]. NatMed,1999.5(6):643-650.
[35]Feng Y, Broder CC, Kenned y PE, et al. HIV-1 entry cofactor:functional cDNA cloning of a seven, transrnem brane. G protein-oou-pied receptor [J]. Science,1996,272(5263):872-877.
[36]Jae Yeol Lee. Kwon Joong Yoon, et al. Catechol-Substituted I Chicoric acid analogues as HIV integrase inhibitors[J]. Bioorganic& Medicinal Chemisry Letters,2003 Dec,13(24):4331-4334.
[37]Rusnati M, Urbinati C, Caputo A, et al. Pentosan po lysulfate as an inhibitor of extracellular HIV-1 Tat [J]. Biol Chem,2001,276 (25): 22420-22425.
[38]Lalezari J P, Eron JJ, Carlson M, et al. A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therap[J]. AIDS,2003,17:691-698.
[2]危健安,陆嘉明等.11省中医药治疗爱滋病项目临床技术培训资料[M].北京：中国中医研究院爱滋病中医药防治中心,2005：1-97.
[3]张学军.皮肤性病学[M](第五版).北京：人民卫生出版社,2002：201.
[4]童迎凯.爱滋病治疗的研究进展[J].生物学通报,2004,10(3)：44.
[5]张娴,方曙.中药防治艾滋病研究进展[J].中国中医药信息杂志,2000,7(1)：20.
[6]中国疾病预防控制中心.艾滋病临床治疗与护理培训教材[M] (第一版),北京：北京大学出版社,2003：194-196.
[7]危健安,陆嘉明等.11省中医药治疗爱滋病项目临床技术培训资料[M].北京：中国中医研究院爱滋病中医药防治中心,2005：2-9.
[8]杨集群,杨成,王莉玲.“AIDS”的中医药治疗[J].吉林中医药,2006,6：5.
[9]何颖.浅析艾滋病的病因病机[J].湖北中医杂志,2002,24(6)：11.
[10]李崇忠等.中医药治疗艾滋病理论的建立和临床应用[J].实用中医内科杂志,2002,16(2)：62-63.
[11]尤松鑫.艾滋病中医证治概述[J],江苏中医,1999,3(20)：3-5.
[12]王健等,中医药治疗艾滋病的现状与思考[J].中国中医药信息杂志,2001,8(12)：8.
[13]吕维柏,“八五”攻关课题中医治疗艾滋病临床总结[A]见：艾滋病人的希望[M].北京：中国中医药出版社,2000：17-26.
[14]王树,在澳大利亚用中医药治疗艾滋病的体会与研讨[J].天津中医,2000,1(1)：45.
[15]姚乃礼,中医证候鉴别诊断学[M](再版).北京：人民卫生出版社,2002：465-462.
[16]李国勤.艾滋病中医辨治体会[J].江苏中医,1994,15(2)：5-6.
[17]黄世敬,危剑安,孙利民等.中医治疗十年以上21例艾滋病例报告[J].中 国医药学报,2004,19(12)：731-732.
[18]唐照亮.中医药、针灸防治艾滋病的研究与探讨[J].安徽中医学院学报,1992,11(1)：2-4.
[19]高学敏主编.中药学[M].北京：人民卫生出版社,2004：1.
[20]宋立人,丁绪亮等主编,现代中药学大辞典[M].北京：人民卫生出版社,2001：5.
[21]云秦川. 中药黄芪的药理研究进展[J].内蒙古中医药,2004(6)：33-34.
[22]刘克敏,刘振玉.黄芪的药理作用及其在运动医学中的应用[J].现代中西医结合杂志,2005,14(17)：2346-2349.
[23]孙延涛,孙琦.黄芪的药理作用研究[J].黑龙江医药,2007,3(20)：256-257.
[24]国家中医药管理局《中华本草》编委会.中华本草精选本[M].上海：上海科学技术出版社,1998：770-774.
[25]李伟,文红梅等.白术质量标准研究[J].药物分析杂志,2001，1(3)：170.
[26]余上才,章育正等.枸杞子和白术免疫调节作用的实验研究[J].上海免疫学杂志,1994,14(1)：12.
[27]中华人民共和国药政管理局.现代实用本草(第1版)[M].北京：人民卫生出版社,1997：248.
[28]国家中医药管理局《中华本草》编委会.中华本草精选本[M].上海：上海科学技术出版社,1998：374-377.
[29]国家中医药管理局《中华本草》编委会.中华本草精选本[M].上海：上海科学技术出版社,1998：725-729.
[30]国家中医药管理局《中华本草》编委会.中华本草精选本[M].上海：上海科学技术出版社,1998：665-667.
[31]李日庆.中医外科学[M].北京：中国中医药出版社,2002：232-233.
[1]王健,许建阳.中医药治疗艾滋病的现状和前景[J].武警医学,2003,14(10)582-584.
[2]中国疾病预防控制中心.艾滋病临床治疗与护理培训教材[M].北京：北京大学医学出版社,2003：194-196.
[3]胡超军.卫生专业技术人员艾滋病防治知识会员培训教材[M].北京：中国市场出版社,2004：114-116.
[4]危剑安.艾滋病的中医药治疗[M]／中国疾病预防控制中心.艾滋病治疗与护理培训教材.北京：北京大学医学出版社,2003：124.
[5]综淑玲,关崇芬,翁新愚等.扶正祛邪中药复方对猴艾滋病模拟实验研究[J].中国实验方剂学杂志,2003,9(1)：42-44.
[6]李志勇,郭勇,罗焕亮.香豆素类化合物——抗HIV天然药物[J].生命的化学,1999,19(4)：197-198.
[7]于志萍,王昌禄,顾晓波大.豆皂苷的研究与进展[J].粮油食品科技,2002,10(3)：1-4.
[8]中国疾病预防控制中心,艾滋病临床治疗与护理培训教材[M](第1版).北京：北京大学出版社,2003：194-196.
[9]赵辨,临床皮肤病学[M](第3版).南京：江苏科学技术出版社,2001：604-607、707-709.
[10]刘翠娥.中药煎剂外用治疗[J].HIV／AIDS疾疗效分析,2005,(10)：839.
[11]顾军,刘洪普.中医药治疗艾滋病研究进展[J].Chinese Genernl practice December2003,6(12):985-986.
[12]张弛,张文远等.针灸治疗艾滋病合并面瘫疗效观察[J].中国针灸,2000,20(8)：489-490.
[13]尹勇,段丽萍.针灸治疗艾滋病23例[J].上海中医药大学学报,2002,16(2)29-30.
[14]张萍,视希娴.甘草及制剂药理有临床应用研究新进展[J].中草药,1987,28(9)：568.
[15]Jordan WE. Three open-label studies of oral interferon alpha in the trearment of HIV disense[J]. J Natl med Assoc,1994,86:47257.
[16]杨秀芝,魏丹芳.抗艾滋病药物的治疗动态[J].天津医学,1995,7(1)：57.
[17]郭大.大蒜在艾滋病中作用(附98例治疗报告)[J].综合临床医学,1994,10(3)：163.
[1]姜日文,姜秀英.艾滋病[J].中国社区医师,2002,18(15)：14.
[2]第十七届国际艾滋病大会[J].上海预防医学杂志,2008,20(9)：455.
[3]骆成榆,黄琴等.艾滋病的病因与致病机制[J].世界感染杂志,2003,3(3)：236.
[4]王家璧.艾滋病[J].北京医学,1982,14(2)：104.
[5]赵武述,膝仁,卞志强.现代临床免疫学[M].北京：人民军医出版社,1994：363—367.
[6]骆成榆,黄琴等.艾滋病的病因与致病机制[J].世界感染杂志,2003,3(3)：234.
[7]Wyagarden JB (ed). Cecil textbook of medicine.19th ed. PhiladelOhia. W BSaurrders Co,1992:1908.
[8]Bevilaegua M, Vago T, Villa M L, et al. An immu-noendocrinological hypothes is of HIV infection. Lanset,1994,343:1552.
[9]闻玉梅.医学分子病毒学[M].北京：人民卫生出版杜,1990：202—220.
[10]王凝芳.艾滋病临床研究进展[J].人民军医,1997,40(10)：605.
[11]比岛恒和.艾滋病与恶性淋巴瘤[J].日本医学介绍,1999,20(6)：259～261.
[12]森山佐知子.艾滋病与机会性感染的病理组织学特征[J].日本医学介,1999,20(6)：265～266.
[13]孟德权,姚宏.艾滋病病理学研究新进展[J].中国药物与临床,2004,4(6)：449.
[14]李太生.艾滋病的抗病毒治疗[J].临床药物治疗杂志,2005,3(5)：13—16.
[15]张耀,熊鸿燕.艾滋病治疗研究进展[J].西南国防医药,200515(5)：557-558.
[16]Borroto-Esoda K, Waters J, et al. Characterization of baseline and treatment emergent resistance mutations following one year of therapy on an entirely once a day regimen including emtricitabine[J]. In Preedings of the Ⅻ International HIV Drug Resistant Workshop,2003 June,10-14.
[17]Margot NA, Isaacson E, et aL ScDoley and M D Nfiller. Genotypic and phenotypic analyses of HIV-1 in antimtroviral-extenced patients tmted with tenofavir[J]. AⅡ,2002,16:1227-1235.
[18]Abdellah Benjahad, J6r6me Guillemont, et al.3-iodo-4-phen oxypyridinones(IOPY S), a new family of highly potent non-nucleoside inhibitors of HIV-1 reverse transcriptase[J]. Bioorganic & Medicinal Chemistry Letters,2003 Dec,13(24):4309-4312.
[19]Haas DW, Zala C, et al. Therapy with atazanavir plus saquinavir in patients failing highly active antiretroviral therapy:a randomized comparative pilot trial [J]. AIIXS,2003 Jun,17(9):1339-1349.
[20]Donnerer J, Kronawetter M, Kapper A, et al. Therapeutic Drug Moni-toting of the Hlv/AIDS Drugs Abacavir。 Zidovudine。 Efavirenz, Nevi-rapine, Indinavir, Lopinavir, and Nelfinavir. Pharmacology,2003, 69(4):197-204.
[21]Kazmierski WM. Bone L, Lawrence W. et al. CCR5 chemokine receptors: gatekeepers of HIV-1 infection. Curr Drug Targets Infect Disord,2002, 2(3):265-278.
[22]Fischl MA. Antiretroviral therapy in 1999 for antiretroviral-naive individualswith HIV infection[J]. AIDS,1999,13(suppl 1):S49-S59.
[23]Hirschel B. Opravil M. The year in review:antiretroviral treatment, [J]. AIDS,1999,13(suppl A):S177-S187.
[24]Chun TW, Davey RT Jr, Eng el D, et al. Re-emergence of HIV after stopping therapy [J]. Nature,1999,401(6756):874-875.
[25]Saag MS, Kilby JM. HIV-1 andHAART:A timeto cure. Atime to kill [J]. Nat Med,1999,5(6):609-611.
[26]Ohtaka H, Schon A, Freire E. Multidmg Resistance to HIV-1 Protease Inhibition Requires Cooperative Coupling between Distal Mutations. Biochemistry,2o03,25.42(46):13659-13666.
[27]艾滋病诊疗指南.中华医学会感染病学分会艾滋病学组制订[J].中华传染病杂志,2006,24(2)：133-144.
[28]Baltimore D. Gene therapy. IntraceUular immunization [J]. Nature.1988.335(6189):395-396.
[29]BleulCC. WuL, Hoxie JA, et al. TheHIV coreceptorscXCR4 and CCR5 are differentially expressed an d regulated on human T lymphocytes [J]. Proc Natl Acad Sci usA,1997,94(5):1925-1930.
[30]0'Brien sJ, DeanM. In search ofAIDS-resistance genes[1]. Sci Am,1997,277(3):44-51.
[31]Heilman cA, timore D. HIV vaccines-where are we going [J]? Nat Med.1998,4(5 Suppl):532-534.
[32]Hilleman MR. A sim plified vaccinologist's vaccinology and the pur-suit of avaccine against AIDS [J]. Vaccine,1998,16(8):778-793.
[33]Dickson D. (1 for governments to back development of AIDS vac-cine[J]. Nature,1999,401(6748):4.
[34]CafaroA. Caputo A. FracassoC, et al. Control of SHIV-89.6P-infection of cynomolgus Fllonkeys by HIV.1 Tat protein vaccine[J]. NatMed,1999.5(6):643-650.
[35]Feng Y, Broder CC, Kenned y PE, et al. HIV-1 entry cofactor:functional cDNA cloning of a seven, transrnem brane. G protein-oou-pied receptor [J]. Science,1996,272(5263):872-877.
[36]Jae Yeol Lee. Kwon Joong Yoon, et al. Catechol-Substituted I Chicoric acid analogues as HIV integrase inhibitors[J]. Bioorganic& Medicinal Chemisry Letters,2003 Dec,13(24):4331-4334.
[37]Rusnati M, Urbinati C, Caputo A, et al. Pentosan po lysulfate as an inhibitor of extracellular HIV-1 Tat [J]. Biol Chem,2001,276 (25): 22420-22425.
[38]Lalezari J P, Eron JJ, Carlson M, et al. A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therap[J]. AIDS,2003,17:691-698.